Acute Lymphoblastic Leukemia (ALL)

First (CR1) / Second Remission (CR2)

Advanced Disease

Autologous or Allogeneic

Matched Related or Unrelated Donor

CCT5001
Phase I
CD19/C22
Chimeric Antigen Receptor(CAR) T Cells in Recurrent/Refractory B Cell Malignancies
Pl: Miklos
Sponsor: Stanford University

BMT343
Phase IIb T-Cell Depleted Graft  + Conventional & Regulatory T Cells in Advanced Hematologic Malignancies
Pl: Meyer
Sponsor: Orca Biosystems Inc.

BMT377
Phase IIb / III in Advanced Hematologic Malignancies Undergoing Allogeneic HCT with Either Orca-T, a T-Cell Depleted Graft w/ Additional Infusion of Conventional T Cells & Regulatory T Cells, or SoC Allogeneic Graft
Pl: Meyer
Sponsor: Orca Biosystems Inc.

BMT342
Phase IIIb to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT
Pl: Johnston
Sponsor: Fred Hutchinson

BMT372
Phase I Reduced intensity Allogeneic HCT in Advanced Hematologic Malignancies w/ Cell DepletedGraft
Pl: Meyer
Sponsor: Stanford University

BMT378
Phase I Trial Evaluating the Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/-CD22 CAR (Chimeric Antigen Receptor) T Cells in Adults with B-Cell Acute Lymphoblastic Leukemia (ALL)
Pl: Muffy
Sponsor: Stanford University

CR / Persistent or Relapsed MRD / and Active Disease

First (CR1) or Higher Remission

Matched Related

Allogeneic

Haplo

Mismatched Unrelated

BMT338
Phase I DonorGrafts DerivedFrom OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
Pl: Meyer
Sponsor: Orca Biosystems

BMT338
Phase I DonorGrafts DerivedFrom OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
Pl: Meyer
Sponsor: Orca Biosystems

BMT391
Phase II
Hi-A-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide in Hematologic Malignancies
Pl: Arai
Sponsor: National Marrow Donor Program (NMDP)